Absci (ABSI) Stock Price Target Increased on Positive Trial Data

H.C. Wainwright has raised its price target for Absci (ABSI) following the release of positive trial data. The new target reflects optimism about the company’s prospects based on the trial performance. While specific figures were not disclosed in the report, this adjustment indicates investor confidence in Absci's future. The price target change could influence investor behavior in the market, potentially affecting Absci's stock performance.

Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.